TD Cowen analyst Joshua Jennings initiated coverage of Anteris Technologies (AVR) with a Buy rating and $15 price target Anteris has developed DurAVR, a first-in-class biomimetic transcatheter aortic valve replacement platform that has “disruptive potential,” the analyst tells investors in a research note. The firm says the hemodynamic outcomes generated in the clinical development program are differentiated and could drive Anteris to capture meaningful share in the $10B TAVR market in replicated in the next trial.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVR: